Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001193125-26-330516
Filing Date
2026-08-03
Accepted
2026-08-03 16:02:04
Documents
2
Period of Report
2026-08-01

Document Format Files

Seq Description Document Type Size
1 3 ownership.html 3  
1 3 ownership.xml 3 1685
2 EX-24.1 klrs-ex24_1.htm EX-24.1 23157
  Complete submission text file 0001193125-26-330516.txt   26467
Mailing Address 300 THIRD STREET CAMBRIDGE MA 02142
Business Address
KEATING LAURIE (Reporting) CIK: 0001620743 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-39409 | Film No.: 261232710

Mailing Address 400 CONNELL DRIVE SUITE 5500 BERKELEY HEIGHTS NJ 07922
Business Address 400 CONNELL DRIVE SUITE 5500 BERKELEY HEIGHTS NJ 07922 650-249-2727
Kalaris Therapeutics, Inc. (Issuer) CIK: 0001754068 (see all company filings)

EIN.: 831971007 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)